deaths (OS)

mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population

versus Standard of Care (SoC)
durvalumab plus tremelimumab vs. Standard of Care (SoC) 1 certainty unassessable-6%
nivolumab plus ipilimumab plus SoC vs. Standard of Care (SoC) 1 certainty unassessablestatistically conclusive-29%